Carbapenem-resistant Acinetobacter
Carbapenem-resistant Acinetobacter baumannii (CRAB) sits in the WHO 2024 "critical priority" tier and the CDC urgent-threat list: it is an opportunistic, often extensively drug-resistant (XDR) nosocomial pathogen that causes ventilator-associated pneumonia, bloodstream infections, wound/burn infections, and device-related infections in ICU patients, frequently leaving only colistin or sulbactam-durlobactam as last-line options. Bacteriophages are well suited to this target because lytic phages kill in a mechanism entirely orthogonal to antibiotics, so resistance to carbapenems, colistin, and other drugs does not confer phage resistance. Many A. baumannii phages also encode capsule depolymerases that strip the protective capsular polysaccharide that drives both virulence and antibiotic evasion, re-sensitizing the organism to host immunity and antibiotics. The first modern Western phage-therapy success — the 2016 "Patterson case" at UC San Diego — was, fittingly, an A. baumannii infection, making CRAB the prototype indication for personalized phage cocktails.
How phages act here
Mechanism
Therapeutic A. baumannii phages are highly strain-specific, binding capsule (K-type) or surface receptors, so cocktails are matched to a patient's isolate by host-range/susceptibility screening, and multiple phages are combined to broaden coverage and suppress the rapid emergence of phage-resistant mutants. A defining feature for this pathogen is phage-encoded depolymerases that enzymatically degrade capsular polysaccharide (CPS), lipopolysaccharide (LPS), and exopolysaccharide (EPS); this both enables phage adsorption and dismantles biofilm, exposing bacteria buried on catheters, ventilators, and abscess walls. The same capsule-stripping produces phage-antibiotic synergy (PAS): depolymerase activity (e.g., Dpo71) destabilizes the outer membrane and improves colistin/polymyxin binding, while sub-lethal antibiotics can boost phage propagation, so combinations consistently outperform either agent alone in vitro and in animal models. Phage resistance, when it arises, frequently comes at a fitness cost — loss or alteration of capsule that re-sensitizes the strain to serum killing and antibiotics — an evolutionary trade-off being deliberately exploited. Engineered and depolymerase-only (enzybiotic) approaches, plus CRISPR-based strategies, are active research angles, though clinical use to date relies on natural lytic cocktails.
Where it stands
Current evidence
Evidence is strongest at the compassionate-use/case-report level and is now moving into early-phase trials. The landmark 2016 UC San Diego case (Schooley/Strathdee, published 2017) used IV and percutaneous personalized 9-phage cocktails (Navy/DoD-derived) to clear a disseminated XDR A. baumannii infection in a critically ill patient. UC San Diego's IPATH (founded 2018, the first North American phage center) reported its first 10 consecutive IV phage cases in 2020 (Aslam et al.), two of which were A. baumannii — one clear success (the index pancreatic/abscess case) and one uninterpretable. As of 2026, phage therapy for CRAB remains predominantly investigational/compassionate-use under FDA single-patient eIND rather than FDA-approved; a 2025 review of non-traditional CRAB agents lists a phage product (PhageBank, formerly Adaptive Phage Therapeutics, now Armata Pharmaceuticals) among six agents in Phase 1/2 trials. Recent primary literature (e.g., a 2026 study isolating phage vB_AbaP_CV1 for CRAB bloodstream infections, combined with polymyxin B in mouse models) continues to validate phage-antibiotic combinations, but no large randomized Phase 3 efficacy trial specific to CRAB has yet reported.
Evidence confidence: medium
The data
Key studies & trials
- Schooley RT, Biswas B, Gill JJ, et al. Development and Use of Personalized Bacteriophage-Based Therapeutic Cocktails To Treat a Patient with a Disseminated Resistant Acinetobacter baumannii Infection. Antimicrobial Agents and Chemotherapy. 2017;61(10):e00954-17. PMID: 28807909. ↗
- Aslam S, Lampley E, Wooten D, et al. Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States. Open Forum Infectious Diseases. 2020;7(9):ofaa389. DOI: 10.1093/ofid/ofaa389. ↗
- Chen X, Liu M, Zhang P, et al. Phage-Derived Depolymerase as an Antibiotic Adjuvant Against Multidrug-Resistant Acinetobacter baumannii. Frontiers in Microbiology. 2022;13:845500. PMID: 35401491. DOI: 10.3389/fmicb.2022.845500. ↗
- Wang L, Wang F, Yuan Z, Liu Y, Jing Y, Xing J. Carbapenem-resistant Acinetobacter baumannii bloodstream infections and specific phages: isolation, analysis and application. Frontiers in Cellular and Infection Microbiology. 2026;16:1774993. PMID: 41994204. DOI: 10.3389/fcimb.2026.1774993. ↗
Who is working on it
Programs & centers
The possibility
If matched-cocktail manufacturing and rapid host-range diagnostics mature, CRAB could become the proving ground where phage therapy graduates from heroic last-resort rescue to a stocked ICU formulary — a curated bank of capsule-typed phages dispensed within hours of a positive culture, the way antibiograms guide antibiotics today. The most compelling near-term wins are likely combination regimens: depolymerase-armed phages cracking open biofilms on ventilators and central lines so that colistin or sulbactam-durlobactam can finish the job, turning two failing therapies into one that works. And because phage-resistant escape so often forces A. baumannii to shed its capsule and surrender to the immune system, clinicians may eventually wield evolution itself as the steering wheel — checkmating the superbug whichever way it runs.